MedTrace Logo

Effectiveness of mRNA Covid-19 Vaccines on Cancer Patients:Observational Study. (ANTICOV)

NCT04878796 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-07-28

No results posted yet for this study

Summary

Based on recent data, COVID (COV) vaccination in cancer patients (pts) is strictly recommended. For oncologic pts,2 types of m-RNA vaccines have been approved: BNT162b2 (Pfizer, Biontech) and mRNA-1273 (Moderna, NIAID). In immunocompetent population, the administration of 2 doses confers 95% protection against COV. However, protection conferred by vaccines, adverse events (AEs) and correlations with antiblastic treatments are unknown in cancer pts.

Conditions

Interventions

DIAGNOSTIC_TEST

Serum collection, adverse events collection

Measuring Abs variation at different timepoints compared to baseline. LIAISON SARS-Cov-2 TrimericS IgG and Elecsys anti-SARS-Cov-2 tests will be adopted. The level of Abs will be evaluated at baseline and 30(±7), 180(±7),365(±7)days after the 2nd dose of vaccine

Sponsors & Collaborators

  • Azienda Socio Sanitaria Territoriale di Cremona

    lead OTHER

Principal Investigators

  • MARGHERITA RATTI, MD · Azienda Socio Sanitaria Territoriale di Cremona (ASST Cremona)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2021-10-31
Completion
2022-05-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04878796 on ClinicalTrials.gov